An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants
Latest Information Update: 31 Oct 2025
At a glance
- Drugs INCB 123667 (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Incyte Corporation
Most Recent Events
- 28 Oct 2025 Status changed from not yet recruiting to recruiting.
- 23 Oct 2025 New trial record